54,223 Shares in Vanda Pharmaceuticals Inc. (VNDA) Acquired by Massachusetts Financial Services Co. MA

Massachusetts Financial Services Co. MA acquired a new stake in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) during the 3rd quarter, according to its most recent disclosure with the SEC. The fund acquired 54,223 shares of the biopharmaceutical company’s stock, valued at approximately $1,245,000. Massachusetts Financial Services Co. MA owned approximately 0.10% of Vanda Pharmaceuticals as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of the business. Metropolitan Life Insurance Co. NY boosted its position in Vanda Pharmaceuticals by 18.4% during the 2nd quarter. Metropolitan Life Insurance Co. NY now owns 17,187 shares of the biopharmaceutical company’s stock valued at $327,000 after acquiring an additional 2,671 shares in the last quarter. Allianz Asset Management GmbH boosted its position in shares of Vanda Pharmaceuticals by 2.9% in the 1st quarter. Allianz Asset Management GmbH now owns 136,218 shares of the biopharmaceutical company’s stock worth $2,295,000 after purchasing an additional 3,903 shares in the last quarter. MetLife Investment Advisors LLC boosted its position in shares of Vanda Pharmaceuticals by 20.0% in the 2nd quarter. MetLife Investment Advisors LLC now owns 24,336 shares of the biopharmaceutical company’s stock worth $464,000 after purchasing an additional 4,063 shares in the last quarter. Strs Ohio boosted its position in shares of Vanda Pharmaceuticals by 9.7% in the 2nd quarter. Strs Ohio now owns 47,500 shares of the biopharmaceutical company’s stock worth $904,000 after purchasing an additional 4,200 shares in the last quarter. Finally, Fox Run Management L.L.C. boosted its position in shares of Vanda Pharmaceuticals by 23.9% in the 2nd quarter. Fox Run Management L.L.C. now owns 28,611 shares of the biopharmaceutical company’s stock worth $545,000 after purchasing an additional 5,516 shares in the last quarter. 93.92% of the stock is currently owned by institutional investors and hedge funds.

VNDA has been the topic of a number of analyst reports. Cantor Fitzgerald reissued a “hold” rating and issued a $26.00 price target on shares of Vanda Pharmaceuticals in a research report on Wednesday, October 3rd. Oppenheimer set a $29.00 price target on Vanda Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday. Stifel Nicolaus set a $31.00 price target on Vanda Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday. Citigroup boosted their price target on Vanda Pharmaceuticals from $27.00 to $31.00 and gave the stock a “buy” rating in a research report on Tuesday, October 16th. Finally, Zacks Investment Research raised Vanda Pharmaceuticals from a “hold” rating to a “buy” rating and set a $26.00 price target on the stock in a research report on Friday, October 12th. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $27.43.

Shares of VNDA opened at $23.81 on Friday. Vanda Pharmaceuticals Inc. has a 52 week low of $11.90 and a 52 week high of $25.07. The company has a market capitalization of $1.05 billion, a PE ratio of -68.03 and a beta of 1.06.

Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its quarterly earnings results on Wednesday, November 7th. The biopharmaceutical company reported $0.13 EPS for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.18. The firm had revenue of $49.13 million for the quarter, compared to analysts’ expectations of $49.44 million. Vanda Pharmaceuticals had a return on equity of 0.68% and a net margin of 0.73%. The business’s revenue for the quarter was up 18.9% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.03) EPS. On average, research analysts predict that Vanda Pharmaceuticals Inc. will post -0.04 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This article was first reported by American Banking News and is owned by of American Banking News. If you are reading this article on another site, it was illegally stolen and reposted in violation of U.S. and international copyright legislation. The original version of this article can be viewed at https://www.americanbankingnews.com/2018/11/10/54223-shares-in-vanda-pharmaceuticals-inc-vnda-acquired-by-massachusetts-financial-services-co-ma.html.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.

Read More: Diversification For Individual Investors

Institutional Ownership by Quarter for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply